A Twelve-week, Double-blind, Placebo-controlled, Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy and Safety of Solriamfetol in the Treatment of Excessive Daytime Sleepiness (EDS) in Patients with Obstructive Sleep Apnea (OSA)

NCT06103825 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

204

Enrollment

INDUSTRY

Sponsor class

Conditions

Sleep Apnea, Obstructive
Excessive Daytime Sleepiness

Interventions

DRUG: Solriamfetol
DRUG: Placebo

Sponsor

Ignis Therapeutics (Suzhou) Limited